In humans, loss-of-function variation in ANGPTL4, particularly p.E40K, is associated with reduced risk of type 2 diabetes and improved insulin sensitivity [15], whereas higher circulating ANGPTL4 has been reported among individuals with type 2 diabetes and metabolic syndrome compared with healthy controls [11,29,30,31]. Here, ANGPTL4 is linked to metabolic syndrome.